News - Page 93 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Post published:September 19, 2022
Post category:Press Release

Read more about the article Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Post published:September 18, 2022
Post category:Press Release

Read more about the article Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

Post published:September 18, 2022
Post category:Press Release

Read more about the article PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson’s Disease and Movement Disorders®

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson’s Disease and Movement Disorders®

Post published:September 16, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Post published:September 16, 2022
Post category:Press Release

Read more about the article Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

Post published:September 15, 2022
Post category:Press Release

Read more about the article Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

Post published:September 15, 2022
Post category:Press Release

Read more about the article MindMed Announces Compliance with Nasdaq Listing Requirements

MindMed Announces Compliance with Nasdaq Listing Requirements

Post published:September 15, 2022
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:September 15, 2022
Post category:Press Release

Read more about the article Sep 13, 2022, 16:50 ET
MINDCURE Announces Financial Results for Fiscal 2022

VANCOUVER, BC, Sept. 13, 2022 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and twelve months…

Sep 13, 2022, 16:50 ET MINDCURE Announces Financial Results for Fiscal 2022 VANCOUVER, BC, Sept. 13, 2022 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and twelve months…

Post published:September 15, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.